Market Intel: Pain Management I: Spinal-Cord Stim To Grab Ever-Bigger Market Share

The field of neuromodulation for treating chronic pain is growing rapidly, especially in the fastest-growing spinal cord stimulation (SCS) market segment, which is expected to hit $2.4bn by 2021. This article, the first of a two-part series, will explore what the key drivers and limitations are for the SCS market and provide insight from three established pain management specialists on what factors will push wider adoption of this therapy.

Doctor holding blue crystal ball with pain sign on medical background.

New advances in spinal cord stimulation (SCS) systems, including those that offer different waveforms and frequencies and better address different populations, have elicited excitement in the medical community. This is especially the case in the US where the opioid epidemic has led to increased scrutiny of doctors' prescription habits and alternative non-drug options for managing pain. Some US legislators and the new US FDA Commissioner, Scott Gottlieb, are also advocating for the use of devices at least as a partial solution to the nation's opioid crisis. (Also see "Gottlieb Touts Devices For Pain Control To Help Solve Opioid Crisis" - Medtech Insight, 6 April, 2017.).

This article, the first of a two-part series focusing on pain management, will delve into the promise of using SCS...

More from Neurology

More from Device Area